<DOC>
	<DOCNO>NCT00653068</DOCNO>
	<brief_summary>This phase III trial study give combination chemotherapy together 3-dimensional conformal radiation therapy autologous peripheral blood stem cell transplant see well work treat young patient atypical teratoid/rhabdoid tumor central nervous system . Giving high-dose chemotherapy autologous peripheral blood stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect store . Chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , Autologous Peripheral Blood Stem Cell Transplant Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor Central Nervous System</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine 6- , 12- , 24-month event-free survival overall survival child ( birth 21 year age ) atypical teratoid/rhabdoid CNS tumor ( AT/RT ) , diagnose base histology , immunophenotyping , modern molecular immunohistochemical analysis INI1 , treat surgery , intensive chemotherapy combine stem cell rescue , radiation therapy . II . To compare outcome young patient ( 3 year old ) study whose histologic diagnosis AT/RT infant identify AT/RT POG-9233 CCG-9921 . SECONDARY OBJECTIVES : I . To determine feasibility toxicity propose chemotherapy regimen combination radiation therapy . II . To contribute tumor sample biologic gene expression data develop yield prognostic indicator provide direction future treatment strategy . III . To develop clinical biologic database future study base . OUTLINE : This multicenter study . Patients stratify accord age tumor histology ( infant [ &lt; 36 month age ] tumor histology immunohistochemical [ IH ] analysis diagnostic atypical teratoid/rhabdoid CNS tumor [ AT/RT ] [ stratum 1 ] v infant INI1 mutation only-based diagnosis [ i.e. , histology consistent AT/RT ] v old child [ ≥ 36 month age ] tumor histology IH analysis diagnostic AT/RT v old child INI1 mutation only-based diagnosis ) . INDUCTION THERAPY AND STEM CELL HARVEST : Patients receive vincristine IV day 1 , 8 , 15 high-dose methotrexate IV 4 hour day 1 . Beginning 24 hour start methotrexate , patient receive leucovorin calcium orally IV every 6 hour serum methotrexate level &lt; 0.1 micromoles . Patients receive etoposide IV 1 hour approximately day 4 , 5 , 6 , cyclophosphamide IV 1 hour approximately day 4 5 , cisplatin IV 6 hour approximately day 6* . Patients also receive filgrastim ( G-CSF ) IV subcutaneously ( SC ) daily begin day 7 continue ANC recovers . When ANC &gt; 1,000/μL post nadir , patient receive G-CSF twice daily stem cell mobilization . Approximately 2-4 day , later peripheral blood stem cell harvest daily , need , course induction therapy total 6 x 10^6 CD34+ cells/kg collect . Treatment repeat every 21 day 2 course . After completion induction therapy , patient re-evaluated . Patients progressive disease remove study . Patients radiographic evidence residual tumor encourage undergo second-look surgery prior proceed radiotherapy consolidation therapy ; patient complete response , partial response , stable disease proceed radiation therapy consolidation therapy depend age , location tumor , initial diagnosis ( whether disease disseminate ) . ** CONSOLIDATION THERAPY AND STEM CELL RESCUE : Within 2-6 week completion induction therapy radiation therapy , patient begin consolidation therapy . Patients receive high-dose carboplatin IV 4 hour high-dose thiotepa IV 2 hour day 1 2 undergo autologous peripheral blood stem cell ( PBSC ) rescue approximately day 4 . Patients also receive G-CSF IV SC daily begin 24 hour stem cell infusion continue ANC recovers . Treatment consolidation therapy follow stem cell rescue repeat every 28 day 3 course absence disease progression unacceptable toxicity . RADIATION THERAPY : *Before ( induction therapy ) consolidation therapy stem cell rescue , patient undergo 3-dimensional conformal radiotherapy ( 3D-CRT ) brain ( spine need ) 5 day week 5-6 week . NOTE : *The administration etoposide , cyclophosphamide , cisplatin dependant prior clearance methotrexate level &lt; 0.1 micromoles . NOTE : **Patients localize posterior fossa tumor ≥ 6 month age end induction therapy OR localize supratentorial tumor diagnosis ≥ 12 month age end induction therapy proceed radiotherapy follow consolidation therapy ; patient disseminate disease diagnosis , patient localize posterior fossa tumor diagnosis &lt; 6 month age end induction therapy , patient localize supratentorial tumor diagnosis &lt; 12 month age end induction therapy proceed consolidation therapy follow radiotherapy . Previously collect tumor tissue analyze mutation INI1 rhabdoid tumor suppressor gene stain INI1 antibody . After completion study treatment , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Rhabdoid Tumor</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Diagnosis CNS atypical teratoid/rhabdoid tumor ( AT/RT ) tumor mutation INI1 gene ( even tumor usual histologic characteristic AT/RT ) Patients extra neural metastasis ( M4 ) renal rhabdoid tumor eligible Patients MRI evidence spinal disease eligible Must undergone definitive surgery past 31 day Cranial MRI ( without gadolinium ) must do preoperatively Postoperatively , cranial MRI ( without gadolinium ) must do , preferably within 48 hour surgery 1028days surgery Entire spinal MRI must obtain either preoperatively ( gadolinium ) postoperatively ( 1028 day surgery ) , prior study enrollment ( without gadolinium ) Life expectancy &gt; 8 week ANC &gt; 1,000/μL Platelet count &gt; 100,000/μL ( transfusion independent ) Hemoglobin &gt; 8 g/dL ( RBC transfusion allow ) Creatinine clearance ( minimum 1224 hour urine collection ) radioisotope GFR ≥ 60mL/min Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2 time ULN age Shortening fraction ≥ 27 % echocardiogram OR ejection fraction ≥ 47 % radionuclide angiogram No evidence dyspnea rest Pulse oximetry &gt; 94 % room air Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior radiotherapy chemotherapy except follow : Patients enrol protocol ACNS0334 whose tumor demonstrate INI1 gene mutation eligible transfer study even receive one course induction therapy ( patient must reconsented treatment restaged ) Prior corticosteroid allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>